Xavier B. Pivot

This paper develops a hydrogel that enables subcutaneous delivery of vesicant antibody-drug conjugates by confining them in a depot, reducing tissue damage while maintaining antitumor efficacy.

This paper develops a hydrogel platform for subcutaneous delivery of trastuzumab, achieving sustained release over 3 days in vitro and in vivo.